Devalingam Mahalingam
Experienced in Thymic Epithelial Tumor

Dr. Devalingam Mahalingam

Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
25 Years of Experience
Experienced in Thymic Epithelial Tumor
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Devalingam Mahalingam is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mahalingam has been practicing medicine for over 25 years and is rated as an Experienced provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Liver Embolization.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Thymic Epithelial Tumor.

Graduate Institution
National University Of Ireland Galway, 2000
Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine - Internal Medicine (Certified)
Fellowships
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Hospital Affiliations
Northwestern Memorial Hospital
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Enrollment Status: Completed
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drugs: Sorafenib, Hydroxychloroquine
Study Phase: Phase 2
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Pembrolizumab, Sorafenib Tosylate
Study Phase: Phase 1/Phase 2
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 18, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 13, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: October 05, 2022
Intervention Type: Biological
Study Drugs: Pembrolizumab, Wild-type Reovirus
Study Phase: Phase 2
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: September 13, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

95 Total Publications

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.
Journal: Cancers
Published: June 30, 2025
Similar Doctors
Marina C. Garassino
Distinguished in Thymic Epithelial Tumor
Dr. Marina C. Garassino
Hematology Oncology | Hematology | Oncology
Distinguished in Thymic Epithelial Tumor
Dr. Marina C. Garassino
Hematology Oncology | Hematology | Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.4 miles away)
773-702-1000
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marina Garassino is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Garassino is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Thymectomy, and Tissue Biopsy. Dr. Garassino is currently accepting new patients.

Distinguished in Thymic Epithelial Tumor
Dr. Amer Sidani
Hematology | Oncology
Distinguished in Thymic Epithelial Tumor
Dr. Amer Sidani
Hematology | Oncology

Northwest Cancer Centers PC

1001 Calumet Ave, 
Dyer, IN 
 (27.0 miles away)
812-220-4476
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amer Sidani is a Hematologist and an Oncologist in Dyer, Indiana. Dr. Sidani is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Advanced in Thymic Epithelial Tumor
Dr. James A. Wallace
Oncology | Geriatrics | Hematology
Advanced in Thymic Epithelial Tumor
Dr. James A. Wallace
Oncology | Geriatrics | Hematology

Primary Healthcare Associates Sc

19550 Governors Hwy 3300, 
Flossmoor, IL 
 (25.3 miles away)
708-915-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Wallace is an Oncologist and a Geriatrics provider in Flossmoor, Illinois. Dr. Wallace is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Pancreatic Cancer, Pancreatoblastoma, and Familial Colorectal Cancer. Dr. Wallace is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mahalingam's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 64 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile